Who we are
GLP1 One Rx publishes editorial reviews and rankings of GLP-1 telehealth providers in the United States, covering semaglutide and tirzepatide. The site is published by GLPONERX LLC.
Every page is researched and edited by Dr. Parmis (Editorial Lead). Every page is medically reviewed by Dr. Jonathan Snipes, MD (Medical Reviewer) and Kim Callender, NP (FNP-BC) (Lead Reviewer).
Providers are scored with our published v4.1 methodology: seven weighted categories, 100 points in total. Providers cannot pay to rank higher.
Dr. Parmis
Editorial Lead
Medical researcher (Western University of Health Sciences). Dr. Parmis researches and edits the content on GLP1 One Rx and leads the editorial work on every page.
Dr. Jonathan Snipes, MD
Medical Reviewer
Dr. Snipes medically reviews every page on GLP1 One Rx. His NPI is 1821250077, and the federal NPPES registry lists him as an active M.D. You can check the record yourself.
Kim Callender, NP (FNP-BC)
Lead Reviewer
Kim Callender reviews every page on GLP1 One Rx. Her NPI is 1144661760, and NPPES lists her as a Family Nurse Practitioner (FNP-BC). You can check the record yourself.
Our scope
This site exclusively covers semaglutide and the broader GLP-1 / GIP therapeutic class. We cover:
- Semaglutide brand-name products: Ozempic, Wegovy, Rybelsus (all manufactured by Novo Nordisk)
- Compounded semaglutide and tirzepatide dispensed by 503A pharmacies and 503B outsourcing facilities
- Comparator GLP-1 / GIP medications: tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity)
- U.S. GLP-1 telehealth providers, scored with the v4.1 methodology (seven weighted categories, 100 points)
- FDA approvals, label expansions, and regulatory actions affecting the class
Why we exist — our editorial mission
The semaglutide telehealth landscape is fragmented and opaque. Patients face wide pricing variation ($99-$1,349/mo), inconsistent pharmacy disclosure, and unclear medical oversight. GLP1 One Rx's mission is to provide patients with clear, sourced answers to a question existing review sites don't answer well: which semaglutide telehealth provider is actually right for me?
What this site is not
- Not a healthcare provider. We do not prescribe medications or operate a pharmacy. Our medical reviewers check content; they do not treat readers.
- Not a pharmacy or insurance broker.
- Not a substitute for medical advice. Information is educational.
- Not affiliated with the FDA, FTC, Novo Nordisk, Eli Lilly, or any government agency.
Ownership
GLP1 One Rx is published by GLPONERX LLC. How the site is funded is stated in the footer of every page and on the affiliate disclosure page. Funding does not change our methodology, rankings or the prices we report.
Contact & corrections
For corrections, provider-data updates, or to suggest a provider for review, email glponerx@gmail.com. We respond to documented corrections within 72 hours.